– Two presentations to highlight the transposon-engineered B lymphocytes ISP™ platform for MPS I and enhancement of muscle mass –
WIRE) –May 12, 2020– Immusoft Corporation, a Seattle-Wash.-based,
leading cell therapy company, today announced two upcoming virtual oral
presentations at the ASGCT 23rd Annual Meeting Virtual Format,
hosted from May 12 – 15, 2020. Registration for the meeting can be accessed at https://www.mylibralounge.com/sites/asgct2020/attendee/.
Dr. Glen Grandea will present, “Follistatin
Overexpression in Sleeping Beauty-Transposed, In Vitro Differentiated Human Plasmablasts:
Enhancement of Muscle Mass and Strength in NSG Mice after Adoptive Transfer” at
5:00 p.m. ET / 2:00 p.m. PT on Thursday, May 14, 2020 during the
Muscolo-skeletal Diseases II session.
On Friday, May 15, 2020, Dr. Chistiane Hampe will present,
“Sleeping Beauty IDUA Transposed Human Plasma Cells for Long-Term Treatment of
an Immunodeficient Murine Model of Mucopolysaccharidosis Type I” at 10:30 a.m.
ET / 7:30 a.m. PT during the Technical Advances in Cell Therapies Session.
Additional information regarding the ISP™ platform can
be found at: https://immusoft.com/technology/
For more information regarding ASGCT please visit: https://www.asgct.org/am20.
“We are excited to have been selected to give two
presentations this year at ASGCT.” Stated Sean Ainsworth, CEO. “The powerful
data in two disparate therapeutic areas speaks clearly to the value of our
platform as a modality for improved delivery of protein therapeutics in a cell
About Immune System Programming (ISP™) Technology
Immusoft’s proprietary ISP™
platform technology is a gene modified cell therapy approach that uses a
clinically validated, non-viral vector that aims to safely and reliably insert
functional genes into immune cells. Once administered back into the patient, a
subset of ISP™ modified cells are expected to reside within survival niches in
the body, continuously producing gene-encoded protein(s). The platform’s broad
utility to produce a wide range of therapeutic protein classes (e.g.
antibodies, signaling proteins, and enzymes), has the potential to disrupt the
current standard of care for many diseases requiring protein injections or
infusions, including many to address orphan diseases.
About Mucopolysaccharidosis type I (MPS I)
MPS I is a rare, lethal childhood
genetic disease that affects the body’s ability to produce IDUA
(alpha-L-iduronidase), which is an essential enzyme that helps to break down
long-chain sugars inside cells. When the sugar chains cannot be broken down and
disposed of, they accumulate in the cells and cause progressive damage. In its
most severe form, and if left untreated, children affected rarely live longer
than ten years after diagnosis.
About Follistatin for Muscle and Strength Enhancement
Follistatin is a naturally occurring protein in the body, which is
involved in increasing muscle mass. One way in which it does so is by
inhibiting a protein, Myostatin, whose function is to keep muscle growth in
check. Follistatin also has
Myostatin-independent activity, which promotes muscle growth and increased
strength. Immusoft is investigating follistatin as a potential therapeutic for
muscle wasting conditions such as muscular dystrophy and ALS.
(immusoft.com) mission is to treat diseases using its breakthrough technology
platform called Immune System Programming (ISP™). The technology modifies a
patient’s B cells and instructs the cells to produce gene-encoded medicines
(biologics). The B cells that are reprogrammed using ISP become miniature drug
factories that are expected to survive in patients for many years. Immusoft
Corporation is based in Seattle, Washington.
Media & Investors
Glenn Schulman, PharmD, MPH
Z3 Biocommunications, LLC
Immusoft makes history with the first engineered B cell investigational therapy cleared for human trials Immusoft seeks to improve the treatment of MPS I, a rare childhood disease, through the use of its Immune System Programming (ISP™) approach that utilizes B cells as re-dosable biofactories…